Bone/Mineral Metabolism News

WASHINGTON — A class of endocrine-disrupting chemicals known as PFAS may work as an “environmental trigger” to drive multiple adverse endocrine health effects, including obesity, thyroid dysfunction and low bone mineral density, although researchers caution that more studies on potential associations are needed.

Severe energy restriction with a total meal replacement diet among postmenopausal women with obesity induced greater weight loss and approximately 1.5-fold as much loss of whole-body lean mass and thigh muscle area compared with moderate energy restriction over 12 months; however, researchers also observed a greater decrease in hip bone mineral density with severe energy restriction, according to findings published in JAMA Network Open

Adults with type 2 diabetes are 55% more likely to sustain an incident vertebral fracture compared with adults without diabetes, with vertebral fracture history further raising the risk for experiencing a nonvertebral fracture, according to findings published in Diabetes Care.

Individuals prescribed high-dose statin therapy to manage cardiovascular risk are more likely to receive a diagnosis of osteoporosis compared with those prescribed a low-dose statin or no therapy, according to findings from a database analysis published in Annals of Rheumatic Diseases.

Regular, weekly physical activity such as walking and yard work can lower the risk for hip or total fracture among postmenopausal women, according to findings published in JAMA Network Open.

Among adult men and postmenopausal women with type 2 diabetes, those who have experienced severe hypoglycemia are at elevated risk for fracture, with risk increasing with greater number of severe hypoglycemic events, according to findings from a study in Japan.

The American Association of Clinical Endocrinologists joined the International Osteoporosis Foundation in support of World Osteoporosis Day on Sunday, calling on health care providers to make osteoporosis and fracture prevention a priority in daily clinical practice, according to a press release.

After a reexamination procedure, a European Medicines Agency committee announced a positive opinion recommending marketing authorization for romosozumab for the treatment of severe osteoporosis in postmenopausal women at high risk for fracture with no history of myocardial infarction or stroke, according to a press release from Amgen and UCB.

Middle-aged women with type 2 diabetes reported more severe musculoskeletal symptoms than women who did not have the condition, according to findings published in The Diabetes Educator.

Adults with obesity who underwent Roux-en-Y gastric bypass experienced an improvement in bone material strength in the year after surgery despite an increase in bone turnover markers and decrease in bone mineral density, according to findings published in Bone.